NASDAQ:ALLO - Allogene Therapeutics News Headlines

$26.19
+0.02 (+0.08 %)
(As of 06/26/2019 12:19 PM ET)
Today's Range
$26.01
Now: $26.19
$26.37
50-Day Range
$25.54
MA: $27.92
$31.27
52-Week Range
$21.67
Now: $26.19
$35.55
Volume4,256 shs
Average Volume508,942 shs
Market Capitalization$3.18 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Allogene Therapeutics (NASDAQ ALLO) News Headlines

Source:
DateHeadline
Allogene Therapeutics Inc (NASDAQ:ALLO) Receives Average Rating of "Buy" from BrokeragesAllogene Therapeutics Inc (NASDAQ:ALLO) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - June 21 at 4:20 PM
Head-To-Head Analysis: Surface Oncology (NASDAQ:SURF) and Allogene Therapeutics (NASDAQ:ALLO)Head-To-Head Analysis: Surface Oncology (NASDAQ:SURF) and Allogene Therapeutics (NASDAQ:ALLO)
www.americanbankingnews.com - June 21 at 4:20 PM
Allogene Therapeutics Inc (NASDAQ:ALLO) Sees Significant Growth in Short InterestAllogene Therapeutics Inc (NASDAQ:ALLO) Sees Significant Growth in Short Interest
www.americanbankingnews.com - June 21 at 5:56 AM
 Analysts Anticipate Allogene Therapeutics Inc (NASDAQ:ALLO) to Post -$0.47 Earnings Per Share Analysts Anticipate Allogene Therapeutics Inc (NASDAQ:ALLO) to Post -$0.47 Earnings Per Share
www.americanbankingnews.com - June 13 at 4:15 AM
Allogene Therapeutics Inc (ALLO) Insider Sells $1,306,637.28 in StockAllogene Therapeutics Inc (ALLO) Insider Sells $1,306,637.28 in Stock
www.americanbankingnews.com - June 5 at 8:21 PM
Allogene Therapeutics (ALLO) Coverage Initiated at Roth CapitalAllogene Therapeutics (ALLO) Coverage Initiated at Roth Capital
www.americanbankingnews.com - June 5 at 8:55 AM
Allogene Therapeutics Announces FDA Clearance of the IND for ALLO-715, a BCMA Allogeneic CAR T (AlloCAR T™) TherapyAllogene Therapeutics Announces FDA Clearance of the IND for ALLO-715, a BCMA Allogeneic CAR T (AlloCAR T™) Therapy
finance.yahoo.com - June 4 at 12:10 PM
Allogene Therapeutics Announces June 2019 Investor Conference ScheduleAllogene Therapeutics Announces June 2019 Investor Conference Schedule
finance.yahoo.com - May 29 at 11:36 AM
Allogene Therapeutics Inc.Allogene Therapeutics Inc.
www.barrons.com - May 15 at 3:44 PM
Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q1 2019 Results - Earnings Call TranscriptAllogene Therapeutics, Inc. (ALLO) CEO David Chang on Q1 2019 Results - Earnings Call Transcript
seekingalpha.com - May 12 at 11:10 AM
Allogene Therapeutics Inc (ALLO) Q1 2019 Earnings Call TranscriptAllogene Therapeutics Inc (ALLO) Q1 2019 Earnings Call Transcript
www.fool.com - May 7 at 11:29 PM
Allogene Therapeutics Reports First Quarter 2019 Financial ResultsAllogene Therapeutics Reports First Quarter 2019 Financial Results
finance.yahoo.com - May 7 at 12:00 PM
Allogene Therapeutics: 1Q Earnings SnapshotAllogene Therapeutics: 1Q Earnings Snapshot
finance.yahoo.com - May 7 at 12:00 PM
2 Big Biotech Stock Upgrades: Can They Reach These Targets?2 Big Biotech Stock Upgrades: Can They Reach These Targets?
finance.yahoo.com - May 5 at 10:47 AM
Allogene Therapeutics Announces Expansion of Scientific Advisory BoardAllogene Therapeutics Announces Expansion of Scientific Advisory Board
finance.yahoo.com - May 1 at 11:49 AM
Allogene Therapeutics to Report First Quarter 2019 Financial Results on May 7, 2019Allogene Therapeutics to Report First Quarter 2019 Financial Results on May 7, 2019
finance.yahoo.com - April 30 at 11:49 AM
Allogene Therapeutics Announces Publication of Preclinical Study Results in Molecular Therapy Highlighting Potential for ALLO-715 (an Anti-BCMA AlloCAR T™ Therapy) in Multiple MyelomaAllogene Therapeutics Announces Publication of Preclinical Study Results in Molecular Therapy Highlighting Potential for ALLO-715 (an Anti-BCMA AlloCAR T™ Therapy) in Multiple Myeloma
finance.yahoo.com - April 15 at 8:48 AM
AskBio Partners with TPG and Vida VenturesAskBio Partners with TPG and Vida Ventures
finance.yahoo.com - April 11 at 8:48 AM
Allogene Therapeutics Announces April 2019 Investor Conference Schedule Allogene Therapeutics Announces April 2019 Investor Conference Schedule 
finance.yahoo.com - April 4 at 9:40 AM
Allogene Therapeutics Presents Preclinical Data Demonstrating the Potential of AlloCAR T™ Therapy in Renal Cell Carcinoma (RCC) at the 2019 AACR Annual MeetingAllogene Therapeutics Presents Preclinical Data Demonstrating the Potential of AlloCAR T™ Therapy in Renal Cell Carcinoma (RCC) at the 2019 AACR Annual Meeting
finance.yahoo.com - April 1 at 3:44 PM
Why this biotech veteran chose to take on cell therapiesWhy this biotech veteran chose to take on cell therapies
www.bizjournals.com - March 20 at 8:42 PM
RSI Alert: Allogene Therapeutics (ALLO) Now OversoldRSI Alert: Allogene Therapeutics (ALLO) Now Oversold
www.nasdaq.com - March 18 at 3:46 PM
All You Need To Know About Allogene Therapeutics, Inc.’s (NASDAQ:ALLO) Financial HealthAll You Need To Know About Allogene Therapeutics, Inc.’s (NASDAQ:ALLO) Financial Health
finance.yahoo.com - March 14 at 10:58 AM
Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q4 2018 Results - Earnings Call TranscriptAllogene Therapeutics, Inc. (ALLO) CEO David Chang on Q4 2018 Results - Earnings Call Transcript
seekingalpha.com - March 9 at 3:33 PM
Allogene Therapeutics IncAllogene Therapeutics Inc
www.bloomberg.com - March 8 at 10:40 AM
Allogene Therapeutics, Inc. to Host Earnings CallAllogene Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - March 8 at 10:40 AM
Allogene Therapeutics Reports Fourth Quarter and Full Year 2018 Financial ResultsAllogene Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
finance.yahoo.com - March 8 at 10:40 AM
Meet Facebook's new neighbor: Cutting-edge cell therapy company lands big East Bay spaceMeet Facebook's new neighbor: Cutting-edge cell therapy company lands big East Bay space
finance.yahoo.com - February 21 at 10:19 AM
Allogene Therapeutics Enters Lease to Build Manufacturing Facility to Develop and Commercialize Allogeneic CAR T (AlloCAR T™) TherapiesAllogene Therapeutics Enters Lease to Build Manufacturing Facility to Develop and Commercialize Allogeneic CAR T (AlloCAR T™) Therapies
finance.yahoo.com - February 20 at 10:01 AM
Allogene Therapeutics Announces February and March 2019 Investor Conference ScheduleAllogene Therapeutics Announces February and March 2019 Investor Conference Schedule
finance.yahoo.com - February 5 at 10:46 AM
Allogene Therapeutics, in Collaboration with Servier, Announces FDA Clearance of the IND for ALLO-501, an anti-CD19 Allogeneic CAR T (AlloCAR T™) TherapyAllogene Therapeutics, in Collaboration with Servier, Announces FDA Clearance of the IND for ALLO-501, an anti-CD19 Allogeneic CAR T (AlloCAR T™) Therapy
finance.yahoo.com - January 28 at 9:37 AM
Debbie Messemer joins PayPals boardDebbie Messemer joins PayPal's board
www.bizjournals.com - January 22 at 3:31 PM
KPMGs former S.F. head Debbie Messemer lands on leading fintechs boardKPMG's former S.F. head Debbie Messemer lands on leading fintech's board
www.bizjournals.com - January 18 at 9:20 PM
Todays Research Reports on Trending Tickers: Novavax and Allogene TherapeuticsToday's Research Reports on Trending Tickers: Novavax and Allogene Therapeutics
finance.yahoo.com - January 14 at 9:45 AM
Allogene Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare ConferenceAllogene Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - December 19 at 3:21 PM
Moderna is sliding in its Wall Street debut after the biggest IPO in biotech historyModerna is sliding in its Wall Street debut after the biggest IPO in biotech history
www.businessinsider.com - December 7 at 3:19 PM
Cambridges Moderna sets record with $604M IPOCambridge's Moderna sets record with $604M IPO
www.bizjournals.com - December 7 at 7:13 AM
Moderna just priced the biggest IPO in biotech history, valuing the startup at $7.5 billionModerna just priced the biggest IPO in biotech history, valuing the startup at $7.5 billion
www.businessinsider.com - December 7 at 7:13 AM
Here's how Moderna's IPO stacks up against others in biotechHere's how Moderna's IPO stacks up against others in biotech
finance.yahoo.com - December 7 at 7:13 AM
Cambridge's Moderna sets record with $604M IPOCambridge's Moderna sets record with $604M IPO
finance.yahoo.com - December 7 at 7:13 AM
Ablexis Announces Licensing Agreement with Allogene TherapeuticsAblexis Announces Licensing Agreement with Allogene Therapeutics
www.bizjournals.com - December 6 at 3:19 PM
Heres how Modernas IPO stacks up against others in biotechHere's how Moderna's IPO stacks up against others in biotech
www.bizjournals.com - December 6 at 6:55 AM
Allogene Therapeutics and Servier Present Pooled Data from Phase 1 Trials of Allogeneic UCART19 inAllogene Therapeutics and Servier Present Pooled Data from Phase 1 Trials of Allogeneic UCART19 in
www.nasdaq.com - December 4 at 6:40 AM
Allogene Therapeutics and Servier Present Pooled Data from Phase 1 Trials of Allogeneic UCART19 in Relapsed/Refractory Acute Lymphoblastic LeukemiaAllogene Therapeutics and Servier Present Pooled Data from Phase 1 Trials of Allogeneic UCART19 in Relapsed/Refractory Acute Lymphoblastic Leukemia
www.streetinsider.com - December 4 at 6:40 AM
Allogene Therapeutics and Servier Present Pooled Data from Phase 1 Trials of Allogeneic UCART19 in Relapsed/Refractory Acute Lymphoblastic Leukemia  Allogene Therapeutics and Servier Present Pooled Data from Phase 1 Trials of Allogeneic UCART19 in Relapsed/Refractory Acute Lymphoblastic Leukemia  
finance.yahoo.com - December 4 at 6:40 AM
Allogene Therapeutics Presents Data from...Allogene Therapeutics Presents Data from...
www.benzinga.com - December 3 at 3:18 PM
Allogene Therapeutics (ALLO) Presents Data from Preclinical Study of ALLO-715 Demonstrating Allogeneic CAR T Potential in MM at ASHAllogene Therapeutics (ALLO) Presents Data from Preclinical Study of ALLO-715 Demonstrating Allogeneic CAR T Potential in MM at ASH
www.streetinsider.com - December 3 at 3:18 PM
Allogene Therapeutics Presents Data from Preclinical Study of ALLO-715 (anti-BCMA) Demonstrating Allogeneic CAR T Potential in Multiple Myeloma at the 2018 ASH Annual MeetingAllogene Therapeutics Presents Data from Preclinical Study of ALLO-715 (anti-BCMA) Demonstrating Allogeneic CAR T Potential in Multiple Myeloma at the 2018 ASH Annual Meeting
finance.yahoo.com - December 3 at 3:18 PM
Morgan Stanley upgrades Teva and Bausch in premarket analyst actionMorgan Stanley upgrades Teva and Bausch in premarket analyst action
seekingalpha.com - November 5 at 3:16 PM
Allogene Therapeutics Announces November 2018 Investor Conference ScheduleAllogene Therapeutics Announces November 2018 Investor Conference Schedule
finance.yahoo.com - November 5 at 8:58 AM
This page was last updated on 6/26/2019 by MarketBeat.com Staff

Featured Article: What is the balance sheet?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel